曲美替尼治疗NRAS突变肿瘤:药物再发现平台研究结果
该研究基于药物再发现平台(DRUP),评估曲美替尼单药治疗NRAS突变晚期实体瘤的疗效与安全性。24例可评估患者中,临床获益率为37.5%,部分缓解率4.2%,中位总生存期9.0个月,中位无进展生存期3.7个月,未发现意外毒性,生物标志物分析未识别出应答相关基因组标志。
要点
- 曲美替尼单药在NRAS突变晚期实体瘤中临床获益率37.5%,部分缓解率4.2%。
- 中位总生存期9.0个月,中位无进展生存期3.7个月。
- 应答与生存未因NRAS密码子Q61对比G12/13或NSCLC对比其他肿瘤而异。
核心结论
- 曲美替尼单药在NRAS突变恶性肿瘤中临床获益有限。
研究设计与样本
- 药物再发现平台(DRUP;NCT02925234)研究,纳入24例可评估的进展性晚期或转移性NRAS突变实体瘤患者,接受曲美替尼单药治疗。
主要发现
- 临床获益(确认完全缓解、部分缓解或稳定疾病≥16周)见于9例患者(37.5%),其中部分缓解1例(4.2%)。
- 中位总生存期为9.0个月(95% CI:5.6 - 13.5),中位无进展生存期为3.7个月(95% CI:3.3 - 5.3)。
- 应答或生存结局在NRAS密码子Q61突变与G12/13突变患者之间无差异,在非小细胞肺癌与其他肿瘤患者之间也无差异。
- 未观察到意外毒性。
- 生物标志物分析未识别出应答或非应答的基因组标志。
临床怎么用
- 对于已耗尽标准治疗选项的NRAS突变晚期实体瘤患者,曲美替尼单药可作为有限临床获益的探索性选择。
局限性
- 样本量小(24例可评估患者),可能限制统计效能与亚组分析可靠性。
- 生物标志物分析未能识别应答相关基因组标志,需进一步探索特定NRAS密码子突变的生物学与临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: NRAS-mutations occur in about 3% of all cancers. Currently, no Food and Drug Administration- (FDA) or European Medicines Agency- (EMA)-approved therapy exists for patients harboring NRAS-mutated malignancies. Trametinib, a MEK1/2 inhibitor, could elicit clinical benefit (CB) in patients harboring NRAS mutations by blocking the MAPK pathway. In the Drug Rediscovery Protocol (DRUP; NCT02925234), we evaluated the clinical efficacy and safety of trametinib monotherapy for the treatment of NRAS-mutated cancers. METHODS: Patients with progressive, advanced and/or metastatic solid malignancies harboring NRAS mutations, who had exhausted all standard treatment options, received trametinib monotherapy. Primary endpoints were CB, defined by RECIST v1.1 as confirmed complete response (CR), partial response (PR), or stable disease (SD) ≥ 16 weeks, and safety. Whole-genome sequencing was performed on pre-treatment biopsies for biomarker analysis. RESULTS: Between January 2017 and February 2024, 24 evaluable patients were included for trametinib monotherapy. CB was observed in nine patients (37.5%), including one partial responder (4.2%). Median overall survival and progression-free survival were 9.0 (95% CI: 5.6 - 13.5) and 3.7 months (95% CI: 3.3 - 5.3), respectively. Response or survival outcomes did not vary between patients with NRAS mutations at codon Q61 versus codon G12/13, nor between patients with non-small cell lung cancer (NSCLC) versus other tumors. No unexpected toxicities were observed. Biomarker analysis did not identify genomic markers for (non)response. CONCLUSION: Trametinib monotherapy offers limited CB in patients harboring NRAS-mutant malignancies. Future research should further explore the biological and clinical significance of specific NRAS codon mutations to identify biomarkers and optimize treatment approaches.
引用
- Verbeek FAJ, Martinez MP, Spiekman IAC, et al. Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol. Eur J Cancer. 2026. PMID: 42361675. doi:10.1016/j.ejca.2026.116906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。